Trademarkia Logo

Canada

C$
PLUS THERAPEUTICS
REGISTERED

on 7 Jun 2023

Last Applicant/ Owned by

PLUS THERAPEUTICS INC.

4200 Marathon Blvd., Suite 200Austin TX 78756

US

Serial Number

2022735 filed on 11th Dec 2019

Registration Number

TMA1183528 registered on 7th Jun 2023

Registration expiry Date

11th Dec 2029

Correspondent Address

AMY CROLL

(Origins IP)1750 Courtwood Crescent, Suite 300Ottawa

ONTARIO

CA

K2C2B5

PLUS THERAPEUTICS

Trademark usage description

nanomedicinal products for medical purposes, namely organic and inorganic pharmaceutical preparations, nanoparticle pharmaceutical preparations, nutra Read More

Vienna Information


24 . 13 . 1

Greek cross, St. Andrew's crossCroix grecque ou de Saint-André

24 . 13 . 14

Crosses accompanied by an inscriptionCroix accompagnée d'une inscription

24 . 17 . 5

Mathematical signsSignes mathématiques

24 . 17 . 7

Mathematical signs combined with figures or lettersSignes mathématiques combinés avec des chiffres ou des lettres

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 8

Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.

Classification Information


Class [005]
Nanomedicinal products for medical purposes, namely organic and inorganic pharmaceutical preparations, nanoparticle pharmaceutical preparations, nutraceuticals, pharmaceuticals, pharmaceutical preparations and substances for the prevention and treatment of cancer, diabetes, infectious diseases, namely, respiratory infections, eye infections, topical infections, autoimmune diseases and disorders, orthopedic diseases and disorders, namely, arthritis, osteoarthritis, bursitis, carpal tunnel syndrome, bone fractures, ligament Injuries, torn meniscus, osteoporosis and scoliosis and chronic back and shoulder pain, blood diseases and disorders, fungal skin infections, diseases and disorders of the central nervous system, namely, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, oncological diseases and disorders, and ophthalmological diseases and disorders; diagnostic chemical reagents for pharmaceutical, medical, and clinical purposes; drug delivery agents in the form of nanoparticle powders that facilitate the delivery of pharmaceutical preparations; liposomal nanoparticle powders being drug delivery agents to facilitate delivery of genetic material and vaccines for medical purposes.


Classification kind code

11

Class [040]
Providing technical information in the field of custom pharmaceutical manufacturing, namely, providing information relating to the chemical, molecular and biomolecular composition and structure of pharmaceuticals; custom manufacture of pharmaceuticals; providing information about custom manufacturing of pharmaceuticals in the nature of oral, inhalatory, intramuscular, intraperitoneal, intratracheal, intratumoral, intravenous, subcutaneous, and topical applied aggregations of liposomes providing time-release of encapsulated pharmaceuticals made to the order or specification of others, for treatment of a wide variety of diseases; custom manufacturing of pharmaceuticals in the nature of oral, inhalatory, intramuscular, intraperitoneal, intratracheal, intratumoral, intravenous, subcutaneous, and topical applied aggregations of liposomes providing time-release of encapsulated pharmaceuticals made to the order or specification of others, for treatment of a wide variety of diseases.


Classification kind code

11

Class [042]
Drug discovery services; pharmaceutical research and development; research and development of nanomedicinal pharmaceuticals; scientific and medical research and development for nutraceuticals, pharmaceuticals, pharmaceutical preparations and substances in the field of cancer, diabetes, infectious diseases, autoimmune diseases and disorders, orthopedic diseases and disorders, blood diseases and disorders, fungal infections, diseases and disorders of the central nervous system, oncological diseases and disorders, and ophthalmological diseases and disorders; scientific research and development for pharmaceuticals in the nature of oral, inhalatory, intramuscular, intraperitoneal, intratracheal, intratumoral intravenous, subcutaneous, and topical applied aggregations of liposomes providing time-release of encapsulated pharmaceuticals, for treatment of a wide variety of diseases; providing medical and scientific information in the fields of drug discovery, nanomedicinal pharmaceuticals, nutraceuticals and pharmaceuticals via a website.


Classification kind code

11

Class [044]
Medical services, namely, administration of nanomedicinal medications; medical services, namely, medical consultancy relating to nanomedicinal products.


Classification kind code

11

Mark Details


Serial Number

2022735

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 24th Aug 2021
Search Recorded
Submitted for opposition 20
on 24th Aug 2021
Examiner's First Report
Submitted for opposition 223
on 24th Aug 2021
Total Provisional Refusal
Submitted for opposition 256
on 16th Feb 2021
Notification of Possible Opposition Sent
Submitted for opposition 135
on 30th Dec 2020
Amendment to Application
Submitted for opposition 257
on 16th Apr 2020
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 15th Apr 2020
Formalized
Submitted for opposition 1
on 15th Apr 2020
Created
Submitted for opposition 228
on 11th Dec 2019
International Registration
Submitted for opposition 30
on 11th Dec 2019
Filed